Cell-type specific posttranslational processing of peptides by different pituitary cell lines.
In order to compare prohormone processing in two distinct pituitary cell types, somatomammotrope cells (GH3) and corticotrope cells (AtT-20) were stably transfected with vectors encoding preproneuropeptide Y (preproNPY) containing four different pairs of basic amino acids at the single endoproteolytic cleavage site: wildtype or KR (lysine-arginine), RR, RK, and KK. The GH-NPY cell lines cleaved proNPY to a similar extent, regardless of the sequence of the basic amino acids at the cleavage site (KR = RR = RK = KK). AtT-20-NPY cells are known to exhibit a strong hierarchy of cleavage site preference when processing wildtype and mutated proNPY forms (KR = RR greater than RK much greater than KK). All four types of GH-NPY and AtT-NPY cells faithfully produced NPY (1-36) NH2 from proNPY (1-69), regardless of the amino acid sequence at the cleavage site. All four types of GH-NPY cells produced some of the expected proNPY-COOH-terminal peptide with Ser40 at its NH2-terminal [proNPY (40-69)]. GH3 cells expressing the RR, RK, and KK forms of proNPY yielded in addition some proNPY-COOH-terminal peptide retaining the amino terminals Lys39 or Arg39 residue. In contrast, AtT-NPY-RK cells produced only the Lys39 form of proNPY-COOH-terminal peptide while the other three AtT-NPY lines (KR, RR, and KK) produced only the Ser40 form of proNPY-COOH-terminal peptide. The residence time of proNPY and NPY in GH3 cells was dramatically increased by treatment with insulin, estradiol, and epidermal growth factor, in concert with the expected increase in PRL synthesis and decrease in GH synthesis; increased residence time in the cells did not result in an increase in the extent of cleavage of proNPY to NPY. AtT-20 cells did not respond to the somatomammotrope-specific set of hormones. Thus, there are several important differences in the posttranslational processing and storage of peptide hormones in corticotropes and somatomammotropes.
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
I M
IM
Dickerson
R E
RE
Mains
D001665:Binding Sites; D002460:Cell Line; D003594:Cytoplasmic Granules / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D015870:Gene Expression; D013006:Growth Hormone / Q000235:genetics / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology; D009154:Mutation; D009478:Neuropeptide Y / Q000096:biosynthesis / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism*; D011388:Prolactin / Q000096:biosynthesis; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D014162:Transfection; D014357:Trypsin
D007328:Insulin; D009478:Neuropeptide Y; D010446:Peptide Fragments; D011498:Protein Precursors; D004958:Estradiol; D004815:Epidermal Growth Factor; D011388:Prolactin; D013006:Growth Hormone; D014357:Trypsin